Ronald S. Go, M.D., engages in health services research, including studies on populations' access to and cost of care, utilization of tests and treatments, and outcome and quality of care. He is particularly interested in secondary data analyses of data sets from Surveillance, Epidemiology and End Results (SEER)-Medicare, the National Cancer Data Base, and Optum Labs.
Dr. Go also investigates the pathogenesis, diagnosis and treatment of histiocytic disorders such as Erdheim-Chester disease, Rosai-Dorfman disease and Langerhans cell histiocytosis as well as complement-mediated hematologic conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome.
- Monoclonal gammopathy of undetermined significance (MGUS). Dr. Go's work involves determining the public health significance of following patients with MGUS.
- Hematologic malignancies. Dr. Go investigates the volume-outcome relationship in the management of hematologic malignancies.
- Health care disparities. Dr. Go's research focuses on socio-demographic as well as geographic disparities in the care and outcomes of hematologic diseases.
Significance to patient care
Dr. Go hopes to determine whether the standard practice of regularly following MGUS patients results in better survival and fewer complications among those whose hematologic malignancies eventually transform into multiple myeloma. Additionally, his research will help determine whether community hematologists-oncologists who see more patients with hematologic malignancies provide better quality of care compared with their counterparts. His overall goal is to reverse the disparity in the care and outcomes of patients with benign and malignant hematologic diseases.